Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-10-05 4:36 pm Purchase |
2023-10-03 | 13D | Madrigal Pharmaceuticals, Inc. MDGL |
Baker Bros. Advisors LP | 2,015,760 9.990% |
470,647 (+30.46%) |
Filing History |
| 2023-08-17 5:12 pm Sale |
2023-08-15 | 13D | Neoleukin Therapeutics, Inc. NLTX |
Baker Bros. Advisors LP | 473,605 19.990% |
-28,549 (-5.69%) |
Filing History |
| 2023-08-10 4:42 pm Sale |
2023-07-31 | 13G | Mereo BioPharma Group plc MREO |
Baker Bros. Advisors LP | 14,604,391 2.200% |
-54,754,968 (-78.94%) |
Filing History |
| 2023-08-10 4:39 pm Sale |
2023-07-31 | 13G | Verastem, Inc. VSTM |
Baker Bros. Advisors LP | 0 0.000% |
-1,345,192 (Position Closed) |
Filing History |
| 2023-08-08 5:16 pm Unchanged |
2023-08-07 | 13D | Madrigal Pharmaceuticals, Inc. MDGL |
Baker Bros. Advisors LP | 1,545,113 8.400% |
0 (Unchanged) |
Filing History |
| 2023-07-19 5:28 pm Purchase |
2023-07-17 | 13D | Neoleukin Therapeutics, Inc. NLTX |
Baker Bros. Advisors LP | 502,154 19.990% |
290,663 (+137.43%) |
Filing History |
| 2023-06-28 5:01 pm Purchase |
2023-06-22 | 13D | IGM Biosciences, Inc. IGMS |
Baker Bros. Advisors LP | 3,277,567 9.990% |
107,673 (+3.40%) |
Filing History |
| 2023-06-16 7:18 pm Unchanged |
2023-06-15 | 13D | Madrigal Pharmaceuticals, Inc. MDGL |
Baker Bros. Advisors LP | 1,545,113 8.400% |
0 (Unchanged) |
Filing History |
| 2023-06-12 4:37 pm Purchase |
2023-05-31 | 13G | Verastem, Inc. VSTM |
Baker Bros. Advisors LP | 1,345,192 8.000% |
1,345,192 (New Position) |
Filing History |
| 2023-06-02 4:06 pm Purchase |
2023-05-25 | 13D | TScan Therapeutics, Inc. TCRX |
Baker Bros. Advisors LP | 2,793,938 6.500% |
9,146 (+0.33%) |
Filing History |
| 2023-05-24 5:11 pm Purchase |
2023-05-23 | 13D | ACADIA Pharmaceuticals Inc. ACAD |
Baker Bros. Advisors LP | 43,227,599 26.500% |
920,810 (+2.18%) |
Filing History |
| 2023-05-24 4:31 pm Purchase |
2023-05-18 | 13D | Prelude Therapeutics Incorporated PRLD |
Baker Bros. Advisors LP | 10,219,080 19.500% |
92,663 (+0.92%) |
Filing History |
| 2023-05-05 4:33 pm Sale |
2023-05-03 | 13D | BeiGene, Ltd. ONC |
Baker Bros. Advisors LP | 152,978,037 13.000% |
-1,337,453 (-0.87%) |
Filing History |
| 2023-05-05 4:24 pm Purchase |
2023-05-05 | 13D | Bellicum Pharmaceuticals, Inc. BLCM |
Baker Bros. Advisors LP | 2,197,919 19.990% |
2,197,919 (New Position) |
Filing History |
| 2023-05-03 4:15 pm Purchase |
2023-05-01 | 13D | Seagen Inc. SGEN |
Baker Bros. Advisors LP | 45,074,469 24.000% |
45,074,469 (New Position) |
Filing History |
| 2023-03-15 4:09 pm Purchase |
2023-03-13 | 13D | Incyte Corporation INCY |
Baker Bros. Advisors LP | 36,641,462 16.400% |
7,108 (+0.02%) |
Filing History |
| 2023-03-13 4:30 pm Purchase |
2023-03-12 | 13D | Seagen Inc. SGEN |
Baker Bros. Advisors LP | 47,233,651 25.300% |
10,043 (+0.02%) |
Filing History |
| 2023-03-10 4:55 pm Purchase |
2023-03-10 | 13D | Talis Biomedical Corporation TLIS |
Baker Bros. Advisors LP | 2,505,086 66.200% |
4,750 (+0.19%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Baker Bros. Advisors LP | 2,368,378 5.100% |
2,368,378 (New Position) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Aravive, Inc. ARAV |
Baker Bros. Advisors LP | 4,586,404 7.500% |
4,586,404 (New Position) |
Filing History |